Anzeige
Mehr »
Login
Mittwoch, 12.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
US-Biotech-Firma sorgt für Furore - steckt hier die Zukunft der Krebsheilung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
253 Leser
Artikel bewerten:
(1)

Reviv Global: REVIV President and CEO Sarah Lomas announces Sela Al Asadi as newly appointed Board Director

Finanznachrichten News

LONDON, Sept. 21, 2022 /PRNewswire/ -- REVIV President and CEO Sarah Lomas today announces that Sela Al Asadi CEO of REVIV UAE will be joining the company's Board of Directors.

Sela Al Asadi CEO of REVIV UAE will be joining the company's Board of Directors

Based out of LA and Dubai, Sela's global reach will be instrumental in the strengthening of REVIV's precision nutrition proposition in the market. Sela's approach towards innovation in skincare and wellness, driven by an extensive wealth of knowledge and experience, will drive forward global research and development, as the company expands its products and services portfolio in the coming years.

Sela co-founded and managed multiple state of the art cosmetic and wellness facilities in the UAE since 2000. Graduating with honors with a degree in Biochemistry and Computer Information Science from Queens University in Canada, she has been able to bridge the gap between technology, wellness and skincare.

Sela initially invested in bringing REVIV to the UAE in 2017 going on to become the CEO of REVIV UAE after expanding her clinic network in the country.

Sela says: "I became interested in REVIV in 2017 while I was researching a wellness partner that would complement the strenuous lifestyle of the executive and athletic world. It was apparent to me that my clientele had an increased demand for wellness optimization which was not being resolved at a conventional medicine level. That's where REVIV came in! Together, we have lived up to our goal to support our clients by keeping their immune systems healthy year-round, by preventing infection and disease and by optimizing energy levels, through our proprietary nutritional solutions.

"I am therefore excited to now be joining the Board of Directors at REVIV, to utilise my knowledge and expertise, as we prepare to launch disruptive technologies across multiple vertical sectors, to drive forward REVIV's global ambitions."

Sarah Lomas, President and CEO of REVIV, says: "The appointment of Sela is exciting as her experience and expertise will help REVIV Global realise the wealth of opportunity to expand our product portfolio across the globe. Our ambitious plans, including a tech-based approach towards precision nutrition, will solidify our position as the number one IV drip therapy company in the world."

About REVIV
REVIV is a life science led provider of nutritional health solutions, and their goal is to be the only personalized nutritional health company that offers precision nutrition solutions, using big data coupled with AI, to evidence that nutrition can have a positive impact on medical conditions or disease. REVIV's vision is to pioneer the democratization of nutrition-based treatments which will reduce disease, extend life and allow people to live better and healthier lives.

For more information about REVIV Global visit our website: www.revivme.com or email Emma Robertson on erobertson@revivme.com

Logo

Photo - https://mma.prnewswire.com/media/1903466/Reviv_Global.jpg
Logo - https://mma.prnewswire.com/media/1428870/REVIV_Global_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/reviv-president-and-ceo-sarah-lomas-announces-sela-al-asadi-as-newly-appointed-board-director-301629772.html

© 2022 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.